Marker Therapeutics company info

What does Marker Therapeutics do?
Marker Therapeutics (NASDAQ:MRKR) is a biopharmaceutical company focused on the development of next-generation T cell-based immunotherapies for the treatment of hematologic malignancies and solid tumor cancers. The company is dedicated to advancing the field of cancer therapy with an innovative approach that involves tailoring treatments to the specific characteristics of a patient's tumor. Marker Therapeutics' projects include a range of multi-tumor antigen T cell therapies aimed at improving the safety and efficacy of cancer treatment. Its objectives are centered on improving patient outcomes through the research and development of targeted therapies that offer a potential for less toxic, more effective cancer care. The company's commitment to innovation and patient care drives its efforts in exploring new pathways and treatments in the fight against cancer.
Marker Therapeutics company media
Company Snapshot

Is Marker Therapeutics a public or private company?

key
Ownership
Public

How many people does Marker Therapeutics employ?

people
Employees
8

What sector is Marker Therapeutics in?

pie chart
Sector
Health Care

Where is the head office for Marker Therapeutics?

location pin
Head Office
Houston, United States

What year was Marker Therapeutics founded?

founded flag
Year Founded
1992
What does Marker Therapeutics specialise in?
/Cancer Immunotherapy /Multi-Antigen T Cell /Tumor Specific Therapy /Adaptive Immunotherapy /Lymphoma Treatment /Clinical Trials

What are the products and/or services of Marker Therapeutics?

Overview of Marker Therapeutics offerings
MultiTAA T cell therapy - an innovative treatment targeting multiple tumor-associated antigens in various cancers.
TPIV200 - a peptide vaccine for treating ovarian and breast cancer.
MT-601 - a multi-antigen targeted T cell therapy for pancreatic cancer.
Cell therapy manufacturing services - providing GMP compliant facilities for cell therapy production.
Research partnerships - collaborating with academic and medical institutions to advance cancer immunotherapy research.

Who is in the executive team of Marker Therapeutics?

Marker Therapeutics leadership team
  • Dr. Juan F. Vera M.D.
    Dr. Juan F. Vera M.D.
    Co-Founder, CEO, President, Treasurer & Director
  • Ms. Elizabeth  Donnelly
    Ms. Elizabeth Donnelly
    Director of Administration
  • Mr. Edmund  Cheung
    Mr. Edmund Cheung
    Vice President of Human Resources
  • Dr. Nadia  Agopyan Ph.D.
    Dr. Nadia Agopyan Ph.D.
    Senior Vice President of Regulatory Affairs
  • Dr. Monic  Stuart M.D.
    Dr. Monic Stuart M.D.
    Chief Medical Officer
  • Patricia  Allison
    Patricia Allison
    Head of Clinical Operations
  • Mr. Michael J. Loiacono
    Mr. Michael J. Loiacono
    Secretary
  • Dr. Robert Z. Florkiewicz Sr.
    Dr. Robert Z. Florkiewicz Sr.
    Senior Director of Molecular Biology & Virology